Return to study ST003117 main page
MB Sample ID: SA341480
| Local Sample ID: | ID_117 |
| Subject ID: | SU003273 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Male and female |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU003273 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Male and female |
Factors:
| Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
|---|---|---|---|---|
| ID_117 | SA341480 | FL040391 | recurrence | Class |
| ID_117 | SA341480 | FL040391 | R | Day |
| ID_117 | SA341480 | FL040391 | CQ+PQ | Treatment |
| ID_117 | SA341480 | FL040391 | Plasma | Sample source |
Collection:
| Collection ID: | CO003266 |
| Collection Summary: | Individuals with P. vivax were admitted at the Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), a reference center for infectious diseases located in Manaus, Western Brazilian Amazon. At inclusion into the CURAVIVAX study, patient socio-demographic data including sex, age, weight, body-mass index and ethnicity was captured. Laboratory analyses were done at pre-treatment through the treatment days and follow-up including the day of recurrence. Patients of both sexes, aged > 6 months, body weight ≥ 5 kg, with symptomatic P. vivax monoinfection, parasite density between 100 and 100,000 parasites/ µL were included. Exclusion criteria included the use of antimalarials in the last 60 days, mixed Plasmodium infections especially P. falciparum, pregnancy, or lactation and concomitant or underlying diseases. Patients with dengue and other febrile diseases were excluded during screening. After confirmation of malaria vivax by thick blood smears, whole blood and plasma samples were collected, aliquoted and stored at -80OC until needed for analysis. Plasma samples for day of inclusion and before treatment (D0), day six (D6), day ninety (D90) and recurrence day (DR) were used for this study. |
| Sample Type: | Blood (plasma) |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR003282 |
| Treatment Summary: | Patients were randomly assigned to one of four treatment groups: Group1- chloroquine (CQ) for 3 days + primaquine (PQ) for 14 days (0.50mg/kg/day) concurrently. Group 2 - dihydroartemisinin/piperaquine (DHA/PPQ) for 3 days + PQ for 14 days (0.50mg/kg/day) concurrently, Group 3 - CQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial CQ, and Group 4 - DHA/PPQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial DHA/PPQ. |
Sample Preparation:
| Sampleprep ID: | SP003280 |
| Sampleprep Summary: | Metabolites were extracted from 150 µL of sample (plasma EDTA), which was mixed with acetonitrile (2:1, v/v; -5 °C) and centrifuged at 15,000 rpm for 15 min to remove proteins. Stable isotopes caffeine-¹³C3, tyrosine-15N and progesterone-d9 were used as internal standards. |
Combined analysis:
| Analysis ID | AN005177 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1220 Infinity |
| Column | Agilent ZORBAX Eclipse Plus C18 (100 x 4.6mm,3.5um) |
| MS Type | ESI |
| MS instrument type | Orbitrap |
| MS instrument name | Thermo Q Exactive Orbitrap |
| Ion Mode | POSITIVE |
| Units | normalized intensity |
Chromatography:
| Chromatography ID: | CH003916 |
| Chromatography Summary: | The binary mobile phases were water 0.5% formic acid with 5 mM of ammonium formate (A), and acetonitrile (B). Their gradient elution started with 20% (B) for 5 min, then linearly increased to 100% (B) in 30 min and kept constant for 8 min in 100% (B). The eluent was restored to the initial conditions in 4 minutes to re-equilibrate the column and held for the remaining 8 minutes. The flow rate was kept at 0.5 mL min-1. The injection volume for analysis was 3 μL, and the column temperature was set at 35 °C. |
| Instrument Name: | Agilent 1220 Infinity |
| Column Name: | Agilent ZORBAX Eclipse Plus C18 (100 x 4.6mm,3.5um) |
| Column Temperature: | 35 |
| Flow Gradient: | gradient elution started with 20% (B) for 5 min, then linearly increased to 100% (B) in 30 min and kept constant for 8 min in 100% (B). The eluent was restored to the initial conditions in 4 minutes to re-equilibrate the column and held for the remaining 8 minutes. |
| Flow Rate: | 0.5 mL/min |
| Solvent A: | 100% water; 0.5% formic acid; 5 mM of ammonium formate |
| Solvent B: | 100% acetonitrile |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS004911 |
| Analysis ID: | AN005177 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | The electrospray ionization was operating with the following settings: spray voltage 3.5 kV; capillary temperature: 269 °C; S-lens RF level 50 V; sheath gas flow rate at 53 L min-1; aux gas flow rate at 14 L min-1; sweep gas flow rate 3 L min-1. The high-resolution mass-spectrometry was obtained under full MS/dd-MS2 mode. The mass range in the full MS scanning experiments was m/z 80-1200. The max IT was set at 200 ms, and AGC target was set at 1 x 106. Resolving power was set at 140,000. |
| Ion Mode: | POSITIVE |
